564 related articles for article (PubMed ID: 26912436)
1. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
[TBL] [Abstract][Full Text] [Related]
2. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
[TBL] [Abstract][Full Text] [Related]
3. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
4. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
[TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
7. Dose-Response and Dose-Toxicity Relationships for Glass
Alsultan AA; van Roekel C; Barentsz MW; Smits MLJ; Kunnen B; Koopman M; Braat AJAT; Bruijnen RCG; de Keizer B; Lam MGEH
J Nucl Med; 2021 Nov; 62(11):1616-1623. PubMed ID: 33741643
[TBL] [Abstract][Full Text] [Related]
8. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
9. Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver.
Edalat F; Camacho JC; Kokabi N; Kendi AT; Galt JR; Kim HS
Clin Nucl Med; 2016 Feb; 41(2):e76-81. PubMed ID: 26447380
[TBL] [Abstract][Full Text] [Related]
10. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
[TBL] [Abstract][Full Text] [Related]
11. Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer.
Lam MG; Louie JD; Abdelmaksoud MH; Fisher GA; Cho-Phan CD; Sze DY
J Vasc Interv Radiol; 2014 Jul; 25(7):1085-93. PubMed ID: 24457263
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
Wagemans MEHM; Kunnen B; Stella M; van Rooij R; Smits M; Bruijnen R; Lam MGEH; de Jong HWAM; Braat AJAT
J Nucl Med; 2024 Feb; 65(2):272-278. PubMed ID: 38176716
[TBL] [Abstract][Full Text] [Related]
13. First Evidence for a Dose-Response Relationship in Patients Treated with
Bastiaannet R; van Roekel C; Smits MLJ; Elias SG; van Amsterdam WAC; Doan D; Prince JF; Bruijnen RCG; de Jong HWAM; Lam MGEH
J Nucl Med; 2020 Apr; 61(4):608-612. PubMed ID: 31601696
[No Abstract] [Full Text] [Related]
14. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
[TBL] [Abstract][Full Text] [Related]
15. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
[TBL] [Abstract][Full Text] [Related]
17. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
18. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
[TBL] [Abstract][Full Text] [Related]
19. Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization.
Sabet A; Ries M; Al-Khalaf Y; Meyer C; Rudlowski C; Simon B; Khreish F; Ezziddin S
Nuklearmedizin; 2019 Jun; 58(3):242-248. PubMed ID: 31167272
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
